JP2011527899A5 - - Google Patents

Download PDF

Info

Publication number
JP2011527899A5
JP2011527899A5 JP2011518016A JP2011518016A JP2011527899A5 JP 2011527899 A5 JP2011527899 A5 JP 2011527899A5 JP 2011518016 A JP2011518016 A JP 2011518016A JP 2011518016 A JP2011518016 A JP 2011518016A JP 2011527899 A5 JP2011527899 A5 JP 2011527899A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
seq
hcmv
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011518016A
Other languages
English (en)
Japanese (ja)
Other versions
JP5475774B2 (ja
JP2011527899A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2008/002683 external-priority patent/WO2010007463A1/en
Publication of JP2011527899A publication Critical patent/JP2011527899A/ja
Publication of JP2011527899A5 publication Critical patent/JP2011527899A5/ja
Application granted granted Critical
Publication of JP5475774B2 publication Critical patent/JP5475774B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011518016A 2008-07-16 2008-07-16 ヒトサイトメガロウイルス中和抗体およびその使用 Expired - Fee Related JP5475774B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/002683 WO2010007463A1 (en) 2008-07-16 2008-07-16 Human cytomegalovirus neutralising antibodies and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013248834A Division JP2014087349A (ja) 2013-12-02 2013-12-02 ヒトサイトメガロウイルス中和抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2011527899A JP2011527899A (ja) 2011-11-10
JP2011527899A5 true JP2011527899A5 (enExample) 2012-05-17
JP5475774B2 JP5475774B2 (ja) 2014-04-16

Family

ID=40430130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011518016A Expired - Fee Related JP5475774B2 (ja) 2008-07-16 2008-07-16 ヒトサイトメガロウイルス中和抗体およびその使用

Country Status (17)

Country Link
EP (2) EP2303923B1 (enExample)
JP (1) JP5475774B2 (enExample)
KR (3) KR20140041951A (enExample)
CN (1) CN102143974B (enExample)
AU (1) AU2008359583B2 (enExample)
BR (1) BRPI0822989A2 (enExample)
CA (1) CA2730620A1 (enExample)
EA (1) EA201170204A1 (enExample)
ES (1) ES2548014T3 (enExample)
IL (1) IL210352A0 (enExample)
MA (1) MA32566B1 (enExample)
MX (1) MX2011000542A (enExample)
NZ (1) NZ591055A (enExample)
PT (1) PT2303923E (enExample)
TN (1) TN2010000616A1 (enExample)
WO (1) WO2010007463A1 (enExample)
ZA (1) ZA201100489B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
PE20141398A1 (es) 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
AU2010334809C1 (en) 2009-12-23 2015-02-26 Agenus Inc. Binding members for human cytomegalovirus
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
CN102286099B (zh) * 2011-08-05 2014-04-09 深圳市卫光生物制品股份有限公司 静注巨细胞病毒人免疫球蛋白及其制备方法
KR102146340B1 (ko) * 2012-03-27 2020-08-24 배리에이션 바이오테크놀로지스 아이엔씨. 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법
CA2879577C (en) * 2012-07-27 2021-08-03 City Of Hope An mva vaccine for delivery of a ul128 complex and preventing cmv infection
WO2014099908A1 (en) * 2012-12-17 2014-06-26 Genentech, Inc. Methods for inhibiting viral infection in transplant patients
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN107325178A (zh) * 2017-06-29 2017-11-07 佛山市南海区普罗圣塔生物科技有限公司 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI871709B (zh) 2020-06-21 2025-02-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白B(gB)多肽
WO2022170074A1 (en) * 2021-02-05 2022-08-11 Amgen Inc. Enhanced hybridoma generation
CN118580343B (zh) * 2022-10-21 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987003602A1 (fr) * 1985-12-06 1987-06-18 Teijin Limited Anticorps monoclonal humain contre le virus megalocytique et procede de preparation dudit anticorps
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
ES2643237T3 (es) * 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
AU2005333155B2 (en) * 2005-03-14 2011-11-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against Hendra and Nipah viruses
US7704510B2 (en) * 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof

Similar Documents

Publication Publication Date Title
JP2011527902A5 (enExample)
JP2024038003A5 (enExample)
JP2022177090A5 (enExample)
JP2021500916A5 (enExample)
JP2018521638A5 (enExample)
JP2010516229A5 (enExample)
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
JP2020535799A5 (enExample)
JP2012525829A5 (enExample)
JP2019527553A5 (enExample)
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
JP2012501669A5 (enExample)
JP2012143232A5 (enExample)
JP2014526898A5 (enExample)
JP2015511817A5 (enExample)
JP2016529882A5 (enExample)
JP2015535828A5 (enExample)
JP2013506428A5 (enExample)
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
RU2014151788A (ru) Молекула, специфически связывающаяся с rsv
JP2023509390A5 (enExample)
JP2016516400A5 (enExample)
JP2023093753A5 (enExample)
US20250145705A1 (en) Gprc5d antibody and application thereof
JP2023545183A5 (enExample)